These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31678267)

  • 21. The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique.
    Valdivieso-Shephard JL; Matas-Pérez E; García-Bujalance S; Mirones-Aguilar I; González-Martínez B; Pérez-Martínez A; López-Granados E; Martínez-Feito A; Sánchez-Zapardiel E
    Cytometry A; 2024 May; 105(5):368-375. PubMed ID: 38327134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
    Hughes-Parry HE; Cross RS; Jenkins MR
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
    Darowski D; Jost C; Stubenrauch K; Wessels U; Benz J; Ehler A; Freimoser-Grundschober A; Brünker P; Mössner E; Umaña P; Kobold S; Klein C
    Protein Eng Des Sel; 2019 Dec; 32(5):207-218. PubMed ID: 31504896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
    Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
    Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.
    Sautto GA; Wisskirchen K; Clementi N; Castelli M; Diotti RA; Graf J; Clementi M; Burioni R; Protzer U; Mancini N
    Gut; 2016 Mar; 65(3):512-23. PubMed ID: 25661083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer.
    Chu W; Zhou Y; Tang Q; Wang M; Ji Y; Yan J; Yin D; Zhang S; Lu H; Shen J
    Biosci Trends; 2018 Jul; 12(3):298-308. PubMed ID: 29899195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide.
    Zhou S; Zhu X; Shen N; Li Q; Wang N; You Y; Zhong Z; Cheng F; Zou P; Zhu X
    Immunopharmacol Immunotoxicol; 2019 Aug; 41(4):490-496. PubMed ID: 31303072
    [No Abstract]   [Full Text] [Related]  

  • 34. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
    Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
    Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 40. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.